SLC22A4 and acute myeloid leukemia: Given that previous investigations demonstrated that low cytarabine uptake in AML cells predicts poor response to therapy17 and taken our data showing uptake and transport efficiency as a major contributor to the enhanced sensitivity of AML cells to gemcitabine we performed knockdown experiments targeting two key transporters involved in nucleoside uptake OCTN1 and ENT120,24.